First Jointly Developed Solution with Volpara
Early Breast Cancer Prediction AI Solution Seeks US FDA Approval
Medical AI company Lunit announced on the 3rd that it unveiled two integrated AI solutions, the first collaboration between Lunit and Volpara Health (hereinafter Volpara), at the '2024 North American Radiology Society (RSNA 2024)' currently being held in Chicago, USA, until the 4th.
Lunit announced plans to build an ‘AI Ecosystem’ based on over 130 million medical imaging and clinical data secured through collaboration with Volpara.
The 'AI Ecosystem' is a comprehensive solution designed to support medical professionals throughout the entire process from cancer diagnosis to treatment and improve patient outcomes. It consists of four core elements: ▲ AI technology for lesion detection and workflow optimization ▲ support for medical decision-making through risk prediction and mammography quality management ▲ integrated solutions to enhance patient engagement ▲ next-generation autonomous AI-based services.
As a practical implementation of the AI Ecosystem, Lunit unveiled ‘Lunit Insight Risk,’ the first integrated solution with Volpara, at RSNA.
Lunit Insight Risk is software that analyzes mammography images to predict a patient’s breast cancer risk within the next 1 to 5 years. While existing breast cancer risk assessment models often rely on statistical trend analysis, this product provides precise risk evaluation by considering various factors such as individual characteristics, race, and ethnic background. Lunit plans to apply for approval from the U.S. Food and Drug Administration (FDA) in the second half of next year and then begin full-scale global sales starting with the North American market.
Lunit also showcased a prototype of an autonomous AI-based ‘Chest X-ray Report Generation’ system. This solution analyzes chest X-ray images and directly generates diagnostic reports, systematically and clearly organizing various patient diagnostic information such as measurements and severity. It is focused on seamless integration with Picture Archiving and Communication Systems (PACS).
Once commercialized, this solution is expected to significantly impact medical imaging interpretation and diagnostic workflows.
Seobum Seok, CEO of Lunit, said, "By combining Lunit’s AI technology with Volpara’s medical data, we can provide medical professionals with more efficient diagnostic tools and offer patients more accurate and early cancer detection services." He added, "Lunit will continue to lead the global cancer diagnosis and treatment market by presenting new possibilities for medical AI through ongoing innovation."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
